Novo Nordisk Philippines lowered suggested retail prices on its once-weekly weight drug, pointing to a rise in adult obesity across the country.
Recap by typeshit. Full story at Manila Standard.
A TV segment airing on WSIL and KFVS looks at the weight loss drug trend and what coverage people might be able to get through their insurance today.
Monthly units climbed from 114,000 in February to 434,000 in September, and sales value rose from ₹48 cr to ₹113 cr as doctors report wider access.
Lilly is lowering what it charges for one of its weight loss drugs. The headline doesn't say which drug or by how much.
Access to Ozempic, Wegovy and Mounjaro in Australia often comes down to who can pay, raising the question of public subsidies.
A short teaser points to UT Health San Antonio work on what GLP-1 medications might do outside weight and metabolic health. Few details are given.
She points to women getting pregnant unexpectedly after GLP-1s restore ovulation, and questions the mixed messages women get about these drugs and fertility.
Loading…